China Resources Sanjiu Medical & Pharmaceutical Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	4.6yrs
Promedio de permanencia en la Junta Directiva	5.2yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

China Resources Sanjiu Medical & Pharmaceutical no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Zheng Liang	CFO & Financial Director	4.6yrs	CN¥2.49m	0.013% CN¥ 7.6m
Hui Zhou	VP, Secretary	22.4yrs	CN¥3.10m	0.013% CN¥ 7.9m
Liang Wang	Vice President	no data	CN¥2.67m	0.010% CN¥ 5.9m
Yongqian Xu	Vice President	less than a year	sin datos	sin datos

4.6yrs

Permanencia media

47yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 000999 se considera experimentado (4.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Hui Zhou	VP, Secretary	19.1yrs	CN¥3.10m	0.013% CN¥ 7.9m
Huawei Qiu	Chairman	6.7yrs	CN¥4.61m	0.019% CN¥ 11.4m
Fang Xu	Independent Director	6.1yrs	CN¥150.00k	sin datos
Xingtian Yao	Independent Director	6.1yrs	CN¥150.00k	sin datos
Ran Tao	Chairman of the Supervisory Board	5.5yrs	sin datos	sin datos
Na Tang	Non-Employee Supervisor	4.9yrs	sin datos	sin datos
Qiang Zhang	Independent Director	less than a year	sin datos	sin datos
Xiaosong Bai	Non-Independent Director	2.2yrs	sin datos	sin datos
Xingpin Cui	Non-Independent Director	2.2yrs	sin datos	sin datos
Yang Don	Director	2.5yrs	CN¥150.00k	sin datos
Jihong Zhang	Supervisor	6.1yrs	sin datos	sin datos
Shutian Yu	Director	1.6yrs	sin datos	sin datos

5.2yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: La junta directiva de 000999 se considera experimentada (5.1 años de antigüedad promedio).

China Resources Sanjiu Medical & Pharmaceutical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

High number of new directors

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new directors

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

High number of new directors

High number of new directors

Recent updates

High number of new directors

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Full year 2023 earnings released: EPS: CN¥2.90 (vs CN¥2.48 in FY 2022)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 23, 2024

Third quarter 2023 earnings released: EPS: CN¥0.53 (vs CN¥0.53 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.75 (vs CN¥0.60 in 2Q 2022)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Announces Implementation of Cash Dividend for 2022, Payable on 15 June 2023

Now 22% undervalued

Full year 2022 earnings released: EPS: CN¥2.48 (vs CN¥2.09 in FY 2021)

Now 20% undervalued

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.53 (vs CN¥0.39 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.60 (vs CN¥0.73 in 2Q 2021)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 12 August 2022

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) agreed to acquire 28% stake in KPC Pharmaceuticals, Inc. (SHSE:600422) from Holley Pharmaceutical Group Co., Ltd and Holley Group Company Limited for CNY 2.9 billion.

First quarter 2022 earnings released: EPS: CN¥0.86 (vs CN¥0.66 in 1Q 2021)

High number of new directors

High number of new directors

Investor sentiment improved over the past week

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Proposes Cash Dividend as of 31 December 2021

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Announces Board Elections

High number of new directors

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.39 (vs CN¥0.51 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.73 (vs CN¥0.54 in 2Q 2020)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Approves Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.66 (vs CN¥0.54 in 1Q 2020)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Proposes Cash Dividend for the Year December 31, 2020

Full year 2020 earnings released: EPS CN¥1.63 (vs CN¥2.16 in FY 2019)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day low: CN¥24.96

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

New 90-day low: CN¥26.02

New 90-day low - CN¥27.00

Earnings released

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

CEO

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad